Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial (Q28185738)

From Wikidata

Jump to navigation Jump to search

scientific article (publication date: 16 June 2001)

Language	Label	Description	Also known as
English	Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial	scientific article (publication date: 16 June 2001)

Statements

scholarly article

0 references

Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial (English)

0 references

0 references

revascularization

1 reference

based on heuristic

inferred from title

acute coronary syndrome

1 reference

based on heuristic

inferred from title

author name string

M L Simoons

1

0 references

language of work or name

0 references

publication date

16 June 2001

0 references

0 references

357

0 references

9272

0 references

1915-24

0 references

Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905060-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Coronary plaque disruption.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905060-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905060-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905060-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction: natural history and the effect of thrombolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905060-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905060-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905060-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905060-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905060-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905060-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905060-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905060-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905060-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905060-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905060-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905060-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905060-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905060-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905060-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905060-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905060-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of abciximab, ticlopidine, and combined Abciximab/Ticlopidine therapy on platelet and leukocyte function in patients undergoing coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905060-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of abciximab induced platelet blockade using a rapid point of care assay

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905060-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905060-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905060-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905060-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905060-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(00)05060-1

0 references

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28185738&oldid=1622291265"